OTC · Biotechnology

Genfit S.a. (GNFTF) Stock

$15.95 +0.00% OTC: GNFTF Healthcare

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments.

Valuation

MetricValue
Price$15.95
Market Cap$799.03M
P/E Ratio-8.14
P/B Ratio-29.52
P/S Ratio10.39
EPS (TTM)$-1.73
52-Week High$15.95
52-Week Low$3.72
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-596.44%
ROA-54.43%
ROCE-66.40%
Gross Margin26.02%
Operating Margin-84.25%
Net Margin-127.40%
Debt/Equity-6.37
Current Ratio2.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$80.0M$20.0M$29.0M$67.0M$65.0M
Operating Profit$32.0M$-27.0M$-27.0M$3.0M$-59.0M
Net Profit$67.0M$-24.0M$-29.0M$2.0M$-86.0M
EPS$1.23$-0.48$-0.58$0.03$-1.73
Op Margin39.7%-135.1%-93.0%4.9%-90.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$282.0M$216.0M$174.0M$151.0M$158.0M
Total Liabilities$163.0M$121.0M$106.0M$82.0M$182.0M
Cash$259.0M$136.0M$78.0M$82.0M$101.0M
Borrowings$74.0M$75.0M$70.0M$62.0M$151.0M

Latest News

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial GlobeNewswire · Jul 8, 2026 GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH GlobeNewswire · Jul 2, 2026 GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma GlobeNewswire · Jun 23, 2026 GENFIT: June 15, 2026 Combined Shareholders Meeting Results GlobeNewswire · Jun 15, 2026 GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH GlobeNewswire · Jun 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$100.0M$-73.0M$-55.0M$15.0M$-25.0M
Investing Cash Flow$-4.0M$-46.0M$0$-2.0M$-5.0M
Financing Cash Flow$-2.0M$-2.0M$0$-1.0M$-19.0M
Net Cash Flow$88.0M$-123.0M$-58.0M$4.0M$29.0M
Free Cash Flow$99.0M$-73.0M$-58.0M$14.0M$-27.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA-124.00
FCF Yield-3.78%
Quick Ratio2.00
Interest Coverage-10.32
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held13.22%
Institutions Held9.71%
Institutions Float Held11.19%
Institutional HolderSharesReport Date
American Century ETF TRT-Avantis Responsible Intl Eqy. ETF4422026-06-30
American Century ETF Trust-Avantis International Small Cap Equity ETF2532026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BRIBFBrii Biosciences Limited $0.13 +0.00% -2.71 $90.69M 0.00%
BXPHFBotanix Pharmaceuticals Limited $0.02 -30.23% -0.41 $29.89M 0.00%
IPHYFInnate Pharma S.A. $1.65 +0.00% -2.84 $154.94M 0.00%
JWCTFJW (Cayman) Therapeutics Co. Ltd $0.20 +0.00% -1.05 $84.22M 0.00%
MLLCFMolecular Partners AG $3.80 +0.00% -2.13 $142.54M 0.00%

About Genfit S.a.

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.

Genfit S.a. is headquartered in FR.

Genfit S.a. (GNFTF) stock trades at $15.95 with a market capitalization of $799.03M. The stock is valued at a price-to-earnings (P/E) ratio of -8.14, price-to-book of -29.52, price-to-sales of 10.39. Over the past 52 weeks the stock has ranged between $3.72 and $15.95, and currently trades at its 52-week high.

On profitability, Genfit S.a. generates a return on equity (ROE) of -596.44%, return on capital employed of -66.40%, an operating margin of -84.25%, a net profit margin of -127.40%.

Official website: www.genfit.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides